Global Phage Therapy in Food Safety Market is Expectd to Witness a CAGR of 4.7%, during the forecast period 2021-2028.
The increased prevalence of food borne diseases that is caused due to food spoilage is boosting the growth of the phage therapy market in food safety, as spoiled food contains pathogenic bacteria and viruses. The interest for characteristic antimicrobial builds has expanded because of changes in shopper positions towards the utilization of substance additives in staple and food handling surfaces. Bacteriophages fit in the class of characteristic antimicrobial and their adequacy in controlling bacterial microbes in agro-food industry has prompted the advancement of various phage items previously endorsed by USFDA and USDA.
Use of bacteriophages on foods and beverage industry, a substantial number of research reports have described the use of bacteriophage biocontrol to target a variety of bacterial pathogens in various foods, ranging from ready-to-eat meats to fresh fruits and vegetables. The number of commercially available products containing bacteriophages approved for use in food safety applications has also been steadily increasing leading to the growth of global bacteriophage market in food safety market.
Regionally, North America holds the major share at present and will remain the leader during the entire forecast period in the phage therapy food safety market. However, Asia Pacific would witness fastest growth during the forecast period as it is a big market with huge population base and many companies are expecxted to invest heavily in this region in the coming years.
The prominent market players in the Global Phage Therapy Market in Food Safety are Armata Pharmaceuticals, Inc. Adaptive Phage Therapeutics, Phagelux, SNIPR BIOME, Microgen Russia, BiomX (MBcure Ltd.), Enbiotix, Eligo Bioscience, MicroPhage Inc., Phage International, Intralytix, Inc, InnoPhage, iNtODEWorld, Locus Biosciences, Bitbiome, PhagoMed Biopharma GmbH, Pherecydes Pharma SA, TechnoPhage, Eliava Biopreparations Ltd., Nextbiotics, PhagePro, Inc, Phi Therapeutics, Fixed-phage Ltd, Micreos BV and ContraFect Corporation among others.